Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2003 Apr 9;17(3):85–89. doi: 10.1002/jcla.10074

Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement

Ching‐Chiang Yang 1,✉, Kang‐Chu Chu 2, Wen‐Meng Yeh 3
PMCID: PMC6807927  PMID: 12696078

Abstract

Vascular endothelial growth factor (VEGF) functions as a regulator of neovascularization in malignant cells. VEGF as a mitogen is thought to alter renal cell carcinoma formation and tumor progression. We investigated the expression of the VEGF gene in order to evaluate its clinical significance in renal cell carcinoma. Tissue samples from 198 patients with renal cell carcinoma were examined with an immunohistochemical stain for the expression of the VEGF gene. The expression rate was compared to 34 normal renal cortical samples obtained from renal surgery from noncancer patients. There were significant differences between normal renal cortex (0%) and cancer tissue (54.5%) in positive staining of VEGF protein (P<0.001). With the progression of tumor grade, the positive rate of VEGF gene expression significantly increased. The expression rate of the VEGF gene in the advanced group, such as with lymph node involvement or vein invasion, was greater than that in the locally confined group (P<0.001). The results revealed that expression of the VEGF gene is proportional to the formation and progression of renal cell carcinoma, which may allow VEGF to be used as a prognostic marker for renal cell carcinoma. J. Clin. Lab. Anal. 17:85–89, 2003. © 2003 Wiley‐Liss, Inc.

Keywords: renal cell carcinoma, vascular endothelial growth factor gene, VEGF

REFERENCES

  • 1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931–10934. [PubMed] [Google Scholar]
  • 2. Liotta LA, Steeg PS, Stetler‐Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327–336. [DOI] [PubMed] [Google Scholar]
  • 3. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039. [PMC free article] [PubMed] [Google Scholar]
  • 4. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964–3968. [PubMed] [Google Scholar]
  • 5. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node‐negative colon cancer. Arch Surg 1997;132:541–546. [DOI] [PubMed] [Google Scholar]
  • 6. Paradis V, Lagha NB, Zeimoura L, et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000;436:351–356. [DOI] [PubMed] [Google Scholar]
  • 7. Sato K, Tsuchiya N, Sasaki R, et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999;90:874–879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343–347. [PubMed] [Google Scholar]
  • 9. Edgren M, Lennernas B, Larsson A, Kalkner KM. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b‐FGF) are not necessarily elevated in patients with advanced renal cell carcinoma. Anticancer Res 2001;21:1423–1430. [PubMed] [Google Scholar]
  • 10. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165–1177. [DOI] [PubMed] [Google Scholar]
  • 11. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211–218. [DOI] [PubMed] [Google Scholar]
  • 12. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757–1763. [DOI] [PubMed] [Google Scholar]
  • 13. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK. Formation of endothelial cell networks. Nature 2000;405:139–141. [DOI] [PubMed] [Google Scholar]
  • 14. Chang SG, Jeon SH, Lee SJ, Choi JM, Kim YW. Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma. Urology 2001;58:904–908. [DOI] [PubMed] [Google Scholar]
  • 15. Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:457–461. [DOI] [PubMed] [Google Scholar]
  • 16. Hemmerlein B, Kugler A, Ozisik R, Ringert RH, Radzun HJ, Thelen P. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch 2001;439:645–652. [DOI] [PubMed] [Google Scholar]
  • 17. Krupski T, Harding MA, Herce ME, et al. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 2001;18:287–302. [DOI] [PubMed] [Google Scholar]
  • 18. West AF, O'Donnell M, Charlton RG, et al. Correlation of vascular endothelial growth factor expression with fibroblast growth factor‐8 expression and clinico‐pathologic parameters in human prostate cancer. Br J Cancer 2001;85:576–583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Cvetkovic D, Movsas B, Dicker AP, et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001;57:821–825. [DOI] [PubMed] [Google Scholar]
  • 20. Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk‐1 in benign, pre‐malignant prostate tissue. Am J Clin Pathol 2001;116:115–121. [DOI] [PubMed] [Google Scholar]
  • 21. Joseph IB, Nelson JB, Denmeade SR, et al. Androgen regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507–2511. [PubMed] [Google Scholar]
  • 22. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329–2333. [PubMed] [Google Scholar]
  • 23. Yano S, Shinohara H, Roy S, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000;60:4959–4967. [PubMed] [Google Scholar]
  • 24. Soker S, Kaefer M, Johnson M, et al. Vascular endothelial growth factor‐mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001;159:651–659. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES